Beta Drugs Ltd
Beta Drugs Q2 FY26: Capex ₹9.45 Cr
Q2 FY26 earnings call: what management guided on revenue, margins and order book.
The short version
Beta Drugs plans to grow at a robust pace of 20-25% annually, as emphasized multiple times in the call. Beta Drugs aims to grow at a consistent pace of 20-25% annually, backed by a robust pipeline and strong execution (Page 15, Rahul Batra closing comments).
From Beta Drugs Ltd's Q2 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- Beta Drugs plans to grow at a robust pace of 20-25% annually, as emphasized multiple times in the call.
- Export sales are expected to see significant growth in the second half of FY26, potentially crossing Rs.100 crores, up from Rs.43 crores in the first half.
- The CDMO business grew 8% YoY and is expected to maintain steady contributions by adding new products and partners.
- In the domestic market, new molecule launches and own branded products are expected to drive growth, including two NDDS products planned for next year.
- The dermatology/cosmetic division aims for Rs.30-50 crores in sales over the next 3-5 years, focusing on scaling current SKUs before launching new ones.
2 more points from Beta Drugs Ltd's call on revenue
Pro opens every point from 15K+ earnings calls
Profitability & Margins
See what Beta Drugs Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Beta Drugs acquired an oncology intermediate plant with a CAPEX of around Rs.9.45 crores; additional Rs.15-20 crores planned for building and machinery to operationalize it within 6-8 months.
- Purchased land for an intermediate plant and a corporate R&D center; final payments pending due to registry processes.
- Fixed asset additions amounting to approximately Rs.25 crores in H1FY26, including expenditure on buildings.
- Cash reserves are being held for new product development, potential inorganic growth opportunities, and in-licensing biosimilars.
2 more points from Beta Drugs Ltd's call on capex
Pro opens every point from 15K+ earnings calls
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Beta Drugs Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- The company had an order book that could not be processed fully by September, resulting in Rs.10-12 crores of orders to be dispatched in October and November (Page 11).
- Exports are tender-driven, with most tenders awarded between October and December, leading to expected higher sales from January onwards (Pages 7 and 12).
- In October alone, three major tenders were filed, with two more planned in different geographies soon (Page 12).
2 more points from Beta Drugs Ltd's call on order book
Pro opens every point from 15K+ earnings calls
Beta Drugs Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest (Q4 FY26): revenue ₹94 Cr, net profit ₹9 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Beta Drugs Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Bajaj Healthcare (Q2 FY26)
For HYE (Half Year Ending) Sept 2025, Total Income reported is ₹299.28 crore. Key investor presentation takeaways from Bajaj Healthcare Ltd's Q2 FY26 investor p
- Infinium Pharma (Q2 FY26)
Revenue from Operations for H1FY26: Rs 84.05 crore, a 1% YoY increase from Rs 82.98 crore in H1FY25 (Page 22). Key investor presentation takeaways from Infinium
- Wanbury (Q2 FY26)
Q2FY26 Revenue from Operations: ₹160.06 Crore . Key investor presentation takeaways from Wanbury Ltd's Q2 FY26 investor presentation — and how it ranks against
- Balaxi Pharma (Q2 FY26)
Revenue for Q2 FY26: ₹56.17 crore . Key investor presentation takeaways from Balaxi Pharma's Q2 FY26 investor presentation — and how it ranks against sector pee
Arthneeti Pro · Annual
Beta Drugs Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Beta Drugs Ltd Q2 FY26 results?
Beta Drugs plans to grow at a robust pace of 20-25% annually, as emphasized multiple times in the call. Beta Drugs aims to grow at a consistent pace of 20-25% annually, backed by a robust pipeline and strong execution (Page 15, Rahul Batra closing comments).
What is Beta Drugs Ltd share price analysis?
Beta Drugs Ltd currently shows a neutral. The stock trades at a P/E of 62.0 with a market cap of ₹2,828 Cr. Investors should review the full earnings analysis for detailed insights.
Is Beta Drugs Ltd planning capital expenditure?
Beta Drugs acquired an oncology intermediate plant with a CAPEX of around Rs.9.45 crores; additional Rs.15-20 crores planned for building and machinery to operationalize it within 6-8 months.
Keep Beta Drugs Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.